MCF7/182R-7 Cell Line

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: MCF7/182R-7 Cell Line
• Alternate name: MCF-7/182R-7; 182R-7
• Cancers detailed: Breast cancer;Fulvestrant resistant
• Research fields: Cancer;Drug development
• Tool sub type: Continuous
• Parental cell: MCF7 S0.5
• Organism: Human
• Gender: Female
• Tissue: Breast
• Donor: Female, Caucasian, 69Y
• Disease: Cancer
• Growth properties: Adherent
• Model: Cancer cell line
• Description: The MCF7/182R-7 cell line is a breast cancer cell line resistant to fulvestrant (Faslodex). The MCF7/182R-7 cell line is a human breast cancer cell line established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 (fulvestrant) in 100 nM concentration. The cellular classification is epithelial, and their shape is polygonal. MCF7/182R-7 cells express oestrogen receptor alpha and do not express progesterone receptor. The passage number of MCF7/182R-7 is 427, 430. Treatment with the steroidal antioestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.
• Application: Investigation of molecular changes
• Production details: The MCF7/182R-7 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, Lykkesfeldt et al (1995). The MCF7/182R-7 cells can be maintained continuously in growth medium with 100 nM fulvestrant.
• Additional notes: Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level. The MCF7/182R-7 cells do not express progesterone receptor. The MCF7/182R-7 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells.
• Cellosaurus id: CVCL_1D41

Target Details

• Target: Oestrogen receptor

Applications

• Application: Investigation of molecular changes
• Application notes: Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level. The MCF7/182R-7 cells do not express progesterone receptor. The MCF7/182R-7 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells. Passage 427(AL3419), 430 (AL3779)

Handling

• Format: Frozen
• Passage number: Passage 427(AL3419), 430 (AL3779)
• Growth medium: Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2.5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance.
• Temperature: 37° C
• Atmosphere: 5% CO2
• Unit size: 1x10^6 cells / vial
• Shipping conditions: Dry ice
• Storage medium: 10% DMSO in FCS.
• Subculture routine: After thawing, dilute the cell suspension with sufficient medium and distribute 5 mL each into T25 flasks to achieve a seeding density of 0.5-1.0 x 10^4 / cm2. Place in a 37°C, 5% CO₂ incubator. Change medium after 24 hours to remove residual DMSO and then every 2-3 days. Subculture routine: Split 1:30 weekly with Trypsin-EDTA for detachment at 37 °C for 5 minutes. Please also see detailed protocol within the Product Datasheet in the Documentation section below.

References

• Thrane et al. 2014. Oncogene. 34(32):4199-4210. PMID: 25362855.
• Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-275. PMID: 18409071.
• Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-179. PMID: 17061041.
• Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194.
• Christensen et al. 2004. Breast Cancer Res Treat. 85(1):53-63. PMID: 15039597.
• Larsen et al. 1997. Int J Cancer. 72(6):1129-1136. PMID: 9378550.
• Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-...

Documentation

• Product Datasheet